Targets › IL33
1 program from 1 company in 3 trials: 3 Phase 3; Respiratory; next expected readout Feb 2027.
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. (UniProt, O95760)
Open in Phaseline: the race on IL33, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Itepekimab (SAR440340) Interleukin-33 inhibitor | IL33 | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Feb 2027 |
Chronic Rhinosinusitis With Nasal Polyps (3)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.